PEP-010 has received orphan drug designation for pancreatic cancer, emphasizing the need for novel treatments in this high-mortality disease. The peptide disrupts Caspase-9 and PP2A interaction, ...
Paris (France), March 17, 2025 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback